Based on the Lantheus Holdings Inc stock forecast from 8 analysts, the average analyst target price for Lantheus Holdings Inc is USD 133.69 over the next 12 months. Lantheus Holdings Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Lantheus Holdings Inc is Slightly Bullish , which is based on 8 positive signals and 5 negative signals. At the last closing, Lantheus Holdings Inc’s stock price was USD 79.76. Lantheus Holdings Inc’s stock price has changed by -12.52% over the past week, -28.91% over the past month and +16.68% over the last year.
No recent analyst target price found for Lantheus Holdings Inc
No recent average analyst rating found for Lantheus Holdings Inc
Company Overview Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. Read Less
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echo...Read More
Frequently Asked Questions About Lantheus Holdings Inc (LNTH) Stock
Based on ratings from 8 analysts Lantheus Holdings Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 16 buy, sell and hold ratings.
Unfortunately we do not have enough data on LNTH's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for LNTH is USD 133.69 over the next 12 months. The maximum analyst target price is USD 175 while the minimum anlayst target price is USD 110.
LNTH stock's Price/Earning ratio is 18.07.
Our analysis grades LNTH stock's Price / Earning ratio at D-. This means that LNTH stock's Price/Earning ratio is above 40% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this LNTH may be fairly valued for its sector
The last closing price of LNTH's stock was USD 79.76.
The most recent market capitalization for LNTH is USD 7.63B.
Based on targets from 8 analysts, the average taret price for LNTH is projected at USD 133.69 over the next 12 months.
This means that LNTH's stock price may go up by +67.61% over the next 12 months.
We can't find any ETFs which contains Lantheus Holdings Inc's stock.
As per our most recent records Lantheus Holdings Inc has 834 Employees.
Lantheus Holdings Inc's registered address is 201 Burlington Road, Bedford, MA, United States, 01730.
You can get more information about it from Lantheus Holdings Inc's website at https://www.lantheus.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Lantheus Holdings Inc (LNTH) Stock
Based on ratings from 8 analysts Lantheus Holdings Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 16 buy, sell and hold ratings.
Unfortunately we do not have enough data on LNTH's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for LNTH is USD 133.69 over the next 12 months. The maximum analyst target price is USD 175 while the minimum anlayst target price is USD 110.
LNTH stock's Price/Earning ratio is 18.07.
Our analysis grades LNTH stock's Price / Earning ratio at D-. This means that LNTH stock's Price/Earning ratio is above 40% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this LNTH may be fairly valued for its sector
The last closing price of LNTH's stock was USD 79.76.
The most recent market capitalization for LNTH is USD 7.63B.
Based on targets from 8 analysts, the average taret price for LNTH is projected at USD 133.69 over the next 12 months.
This means that LNTH's stock price may go up by +67.61% over the next 12 months.
We can't find any ETFs which contains Lantheus Holdings Inc's stock.
As per our most recent records Lantheus Holdings Inc has 834 Employees.
Lantheus Holdings Inc's registered address is 201 Burlington Road, Bedford, MA, United States, 01730.
You can get more information about it from Lantheus Holdings Inc's website at https://www.lantheus.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LNTH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
